Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Otolaryngol Allied Sci ; 19(1): 79-84, 1994 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8174308

RESUMO

In a prospective study the effects on the voice of nandrolone decanoate super-imposed on cyclical hormonal replacement therapy (HRT) given to post-menopausal women suffering from a severe form osteoporosis were compared with the effects of HRT alone. Comparing the experimental group with the control group, after one year of medication in the experimental group a higher percentage of patients had: a lower fundamental frequency during speech, a loss of high frequencies and an increase in voice instability and creakiness. The lowering of the frequencies and the increase of instability can be explained by histological changes in the vocal cords and by problems in the adaptation to these histological changes.


Assuntos
Anabolizantes/efeitos adversos , Nandrolona/análogos & derivados , Pós-Menopausa , Virilismo/induzido quimicamente , Distúrbios da Voz/induzido quimicamente , Idoso , Anabolizantes/uso terapêutico , Estudos de Casos e Controles , Edema/induzido quimicamente , Terapia de Reposição de Estrogênios , Feminino , Humanos , Laringoscopia , Pessoa de Meia-Idade , Nandrolona/efeitos adversos , Nandrolona/uso terapêutico , Decanoato de Nandrolona , Osteoporose Pós-Menopausa/tratamento farmacológico , Fonação/efeitos dos fármacos , Estudos Prospectivos , Fatores de Tempo , Voz/efeitos dos fármacos , Qualidade da Voz/efeitos dos fármacos
2.
Bone Miner ; 18(3): 251-65, 1992 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-1392698

RESUMO

Thirty-six women with postmenopausal osteoporosis (31 of them with at least one non-traumatic vertebral compression fracture) were matched pair-wise as to age, years since menopause and body mass index and randomized to receive either cyclical estrogen-progestagen replacement treatment (group 1) or the same treatment plus nandrolone decanoate (group 2). During the first year of treatment in both groups the forearm BMC (SPA) rose proximally and distally 2-3%. Over 2 years the increments of forearm BMC in both groups were up to 4.5%. Lumbar BMC (DPA) rose in both groups nearly 10% over the first year and 12-12.5% over 2 years. The cancellous bone density of L3 (QCT) showed in 6 months an increase of 21% in group 1 and 29% in group 2 to subsequently stay at that level. All these changes from the basal levels were highly significant but there were no significant differences between the two groups. These two conclusions were also drawn with regard to the induced fall of serum alkaline phosphatase (-23%), osteocalcin (-35% to -44%) and procollagen I (-15% to -22%) and of the fasting urinary hydroxyproline (-33% to -36%). No significant increase in the number of newly deformed vertebrae occurred in 2 years.


Assuntos
Densidade Óssea , Terapia de Reposição de Estrogênios , Nandrolona/uso terapêutico , Osteoporose Pós-Menopausa/tratamento farmacológico , Idoso , Fosfatase Alcalina/sangue , Cálcio/sangue , Colesterol/sangue , HDL-Colesterol/sangue , Quimioterapia Combinada , Estradiol/efeitos adversos , Estradiol/análogos & derivados , Estradiol/uso terapêutico , Terapia de Reposição de Estrogênios/efeitos adversos , Feminino , Humanos , Hidroxiprolina/urina , Pessoa de Meia-Idade , Nandrolona/efeitos adversos , Osteocalcina/sangue , Método Simples-Cego , Distúrbios da Voz/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...